Cellectis (CLLS) EBIT Margin (2015 - 2026)

Cellectis' (CLLS) quarterly EBIT Margin came in at 435.64% in Q1 2026, down 30257.0% year-on-year from N/an in Q1 2025, and down 219.25% quarter-over-quarter from 136.46% in Q4 2025.

Cellectis (CLLS) EBIT Margin (2015 - 2026) Analysis & Trends

Cellectis' EBIT Margin history runs 12 years deep, the most recent figure standing at 435.64% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 30257.0% year-over-year to 435.64% in Q1 2026; TTM through Mar 2026 was 62.6%, a 4833.0% increase from a year earlier, with the FY2025 full-year figure at 81.64%, up 6185.0% from the prior year.
  • EBIT Margin fell to 435.64% in Q1 2026 per CLLS's latest filing, from 136.46% in the prior quarter.
  • Across five years, EBIT Margin topped out at 22.86% in Q3 2025 and bottomed at 16856.83% in Q1 2023.
  • The 5-year median for EBIT Margin is 435.64% (2026), against an average of 4411.23%.
  • Across the five-year window, EBIT Margin slumped 1512056 bps in 2022 and surged 1639539 bps in 2024, its largest moves.
  • Year by year, EBIT Margin stood at 35.32% in 2022, then slumped by 29490 bps to 10451.94% in 2023, then soared by 99 bps to 83.99% in 2024, then plunged by 62 bps to 136.46% in 2025, then slumped by 219 bps to 435.64% in 2026.
  • Per Business Quant, the three latest CLLS EBIT Margin figures stand at 435.64% (Q1 2026), 136.46% (Q4 2025), and 22.86% (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 16.51%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 38.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 17.83%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 31.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Cellectis 281.48 Mn 95.81 Mn - -435.64%

Historic Data

Download Data
DateValue
Mar 31, 2026 -435.64%
Dec 31, 2025 -136.46%
Sep 30, 2025 22.86%
Jun 30, 2025 -57.32%
Mar 31, 2025 -133.07%
Dec 31, 2024 -83.99%
Sep 30, 2024 -66.48%
Jun 30, 2024 -213.51%
Mar 31, 2024 -461.44%
Dec 31, 2023 -10,451.94%
Sep 30, 2023 -13,336.13%
Jun 30, 2023 -13,270.22%
Mar 31, 2023 -16,856.83%
Dec 31, 2022 -35.32%
Sep 30, 2022 -15,630.29%
Jun 30, 2022 -2,089.75%
Mar 31, 2022 -1,755.44%
Dec 31, 2021 -239.33%
Sep 30, 2021 -509.72%
Jun 30, 2021 -335.37%